🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨

Referências:
1. Bush, Karen, and Patricia A Bradford. “Epidemiology of β-Lactamase-Producing Pathogens.” Clinical microbiology reviews vol. 33,2 e00047-19. 26 Feb. 2020, doi:10.1128/CMR.00047-19 (https://pubmed.ncbi.nlm.nih.gov/32102899/ )
2. Tamma, Pranita D., et al. "Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections." Infectious Diseases Society of America (2023).(https://www.idsociety.org/practice-guideline/amr-guidance/ )
3. BrCAST Resistência Intrínseca e Fenótipos Raros versão 3.2 do EUCAST Fevereiro 2020 (https://brcast.org.br/wp-content/uploads/2022/09/Resiste%CC%82ncia-Intri%CC%81nseca-e-Feno%CC%81tipos-Raros-BrCAST-16-9-2021.pdf )
4. Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521-547. doi:10.1016/j.cmi.2021.11.025
5. Giannella M, Trecarichi EM, Giacobbe DR, et al. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2018;51(2):244-248. doi:10.1016/j.ijantimicag.2017.08.019
6. Li YY, Wang J, Wang R, Cai Y. Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):408. Published 2020 Jun 11. doi:10.1186/s12879-020-05133-0